A CD39+ Treg subset could be a potential biomarker of the inflammatory activity in MS, and in this regard, a deficit in CD39+CD4+CD25+FoxP3+ Treg was seen in RRMS patients but not in SPMS patients compared with HCs. This evidence concerns the gene CD4 and myeloid sarcoma.